Key Documents
Frank M. Longo, M.D., Ph.D.
- Professor, Neurology & Neurological Sciences
Contact Information
- Clinical Offices
Neurology Department 300 Pasteur Dr H3160 MC 5235 Stanford, CA 94305 Telephone Work (650) 723-5072 Fax (650) 725-7459
- Academic Offices
Personal InformationAdministrative Contact Diane Madsen Admin Associate Email dmadsen@stanford.edu Tel Work 650-724-3172Not for medical emergencies or patient use
Clinical Focus
- Neurology
- Alzheimer's Disease
- Huntington Disease
Administrative Appointments
- Professor and Chair, Department of Neurology and Neurological Sciences, Stanford University , (2006– present )
- Professor and Chair, Department of Neurology, University of North Carolina, Chapel Hill , (2001– 2005 )
- Professor and Vice Chair, UC San Francisco , (1999– 2001 )
- Assoc. Chief of Staff for Research and Dev., SF, VAMC , (1997– 2001 )
- Assoc. Professor and Vice Chair, UC San Francisco , (1996– 1999 )
- Chief, Neurology and Rehab Services, SF, VAMC , (1995– 2001 )
Honors and Awards
- Stanford University Fellow, Stanford University (2006-2008)
- Outstanding Alumnus Award, UC San Diego (2000)
- Associate Editor, Annals of Neurology (1994-1997)
- Beeson Award, American Federation for Aging Research (1995)
- Edwin Boldrey Award for Basic Science Research, San Francisco Neurological Society (1990)
- First Place in Neuroscience, National Student Research Forum (1979)
Professional Education
- Board Certification: Neurology, American Board of Psychiatry and Neurology (1989)
- UCSF Medical Center (1987) CA USA
- New York VA Medical Center (1984) NY
- UC San Diego (1981) CA USA
- Ph.D., UC San Diego Neuroscience (1983)
- M.D., UC San Diego Medicine (1981)
- BA, UC San Diego Biology (1977)
Graduate & Fellowship Program Affiliations
Industry Relationships
Stanford is committed to ethical and transparent interactions with our industry partners. It is our policy to disclose payments of $5,000 or more, equity valued at $5,000 or more in a publicly traded company, or any equity in a privately held company, to physicians and scientists employed by Stanford University from companies or other commercial entities with which they interact as part of their professional activities.
- Equity: PharmatrophiX
Research Interests
Clinical interests include Alzheimer’s disease and Huntington’s disease and the development of effective therapeutics for these disorders.
Our research group is focused on the discovery of cellular signaling mechanisms that serve as a basis for the development of novel therapeutic approaches for Alzheimer’s disease, Huntington’s disease and other neurological disorders. In our Neurotrophin Program, we have pioneered the development of small molecule ligands targeted to neurotrophin receptors to promote novel signaling mechanisms. Small molecule-induced activation of these mechanisms demonstrates therapeutic efficacy in models of Alzheimer’s disease, Huntington’s disease, Parkinson’s disease, spinal cord injury, amyotrophic lateral sclerosis (ALS), HIV dementia and other areas. These novel compounds also promote neurogenesis from stem cells.
In our Protein Tyrosine Phosphatase Receptor Program we have elucidated the role of protein tyrosine phosphatase (PTP) receptors in the nervous system by focusing on LAR, a prototype PTP receptor that we discovered to be expressed in the nervous system. Our studies demonstrated the first CNS and PNS phenotypes in a PTP receptor mutant mouse, discovered PTP extracellular domains responsible for their potent neurite promoting effects, found that LAR associates with Trk neurotrophin receptors to regulate their activity, showed that down regulating LAR promotes stem cell proliferation and stimulates hippocampal neurogenesis, and developed a novel approach for down regulating PTP activity. This work reveals additional candidate therapeutic targets for small molecule development.
Publications
- Curr Med Chem. 2009; (11): 1355-65
- J Neurosci. 2009; (34): 10627-37
- PLoS One. 2008; (11): e3604
- J Biol Chem. 2008; (35): 23950-5
- CNS Neurol Disord Drug Targets. 2008; (1): 63-70
- Neurotoxicology. 2008; (4): 605-12
- Mol Cell Neurosci. 2007; (3): 481-92
- Curr Alzheimer Res. 2007; (5): 503-6
- J Biol Chem. 2006; (24): 16482-92
- Eur J Neurosci. 2006; (6): 1575-80
- J Neurosci. 2006; (20): 5288-300
- Mol Cell Neurosci. 2006; (4): 723-38
- Curr Alzheimer Res. 2006; (1): 5-10
- J Neurobiol. 2006; (13): 1420-36
- Curr Alzheimer Res. 2005; (2): 167-9
- Eur J Neurosci. 2005; (9): 2159-70
- Curr Med Chem - CNS Agents. 2005; 29-41
- NeuroRx. 2004; (1): 117-27
- J Alzheimers Dis. 2004; (6 Suppl): S13-7
- J Neurosci. 2003; (8): 3353-63
- J Mol Neurosci. 2003; (3): 323-6
- DNA Cell Biol. 2003; (5): 303-15
- J Mol Neurosci. 2002 Aug-Oct; (1-2): 107-11
- J Neurosci. 2002; (24): 10539-48
- Neuron. 2002; (3): 375-86
- J Neurosci. 2001; (14): 5130-8
- Am J Med Genet. 2001; (3): 188-92
- Carcinogenesis. 2000; (2): 125-31
- J Neurobiol. 2000; (4): 477-86
- J Biol Chem. 2000; (38): 29868-74
- Prog Brain Res. 2000; 333-47
- Brain Res. 2000; (2): 203-8
- J Neurosci Res. 1999; (2): 230-7
- Mol Carcinog. 1999; (2): 139-49
- Mol Cell Neurosci. 1998; (5/6): 271-86
- Brain Res Mol Brain Res. 1998; (1): 1-12
- Mol Cell Neurosci. 1998; (5-6): 271-86
- J Neurosci. 1997; (20): 7594-605
- J Neurosci Res. 1997; (1): 1-17
- Diabetes. 1997; (4): 647-52
- J Neurosci Res. 1997; (3): 348-60
- Nat Biotechnol. 1996; (9): 1092
- J Neurosci Res. 1995; (6): 807-19
- J Cell Biol. 1995; (3): 415-31
- Ann Neurol. 1994; (2): 125-7
- J Biol Chem. 1993; (35): 26503-11
- Neurochem Int. 1993; (6): 575-82
- J Neurosci Res. 1993; (3): 325-35
- Neuroscience. 1993; (3): 597-604
- Ann N Y Acad Sci. 1993; 288-90
- J Neurosci Res. 1992; (4): 605-16
- Cell Regul. 1990; (2): 189-95
- Genet Anal Tech Appl. 1990; (5): 142-3
- Exp Neurol. 1990; (3): 274-83
- Prog Brain Res. 1990; 227-38
- Prog Neurobiol. 1989; (2): 87-134
- Neuron. 1989; (5): 655-64
- Radiology. 1988; (2): 445-8
- Muscle Nerve. 1986; (5): 385-93
- J Neuropathol Exp Neurol. 1986; (2): 151-60
- Brain Res. 1984; (1): 105-17
- Exp Neurol. 1984; (1): 207-18
- J Comp Neurol. 1983; (4): 460-70
- Exp Neurol. 1983; (3): 756-69
- J Cell Biol. 1983; (6): 1882-90
- Brain Res. 1983; (1): 57-66
- Brain Res. 1983; (1): 109-16
- Brain Res. 1983; (1): 47-56
- J Hand Surg Am. 1982; (6): 580-7
- Science. 1982; (4562): 860-1
- J Neuropathol Exp Neurol. 1982; (4): 412-22
- Exp Neurol. 1982; (2): 361-75
- Brain Res. 1982; (2): 277-94
- Brain Res. 1982; (1): 157-61
- J Neurosci Res. 1982; (2-3): 241-50
- Adv Neurol. 1982; 453-72
- Brain Res. 1980; (2): 471-85